FR14C0019I1 - - Google Patents
Info
- Publication number
- FR14C0019I1 FR14C0019I1 FR14C0019C FR14C0019I1 FR 14C0019 I1 FR14C0019 I1 FR 14C0019I1 FR 14C0019 C FR14C0019 C FR 14C0019C FR 14C0019 I1 FR14C0019 I1 FR 14C0019I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8986698P | 1998-06-19 | 1998-06-19 | |
US10478798P | 1998-10-19 | 1998-10-19 | |
PCT/IB1999/001100 WO1999065908A1 (en) | 1998-06-19 | 1999-06-14 | PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
Publications (2)
Publication Number | Publication Date |
---|---|
FR14C0019I1 true FR14C0019I1 (el) | 2014-04-11 |
FR14C0019I2 FR14C0019I2 (fr) | 2015-01-02 |
Family
ID=26781018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR14C0019C Active FR14C0019I2 (fr) | 1998-06-19 | 2014-03-07 | COMPOSES DE PYRROLO 2,3d]PYRIMIDINE |
Country Status (41)
Country | Link |
---|---|
US (3) | US6610847B2 (el) |
EP (1) | EP1087970B1 (el) |
JP (3) | JP4666762B2 (el) |
KR (1) | KR100415791B1 (el) |
CN (1) | CN1128800C (el) |
AP (1) | AP1021A (el) |
AR (1) | AR016499A1 (el) |
AT (1) | ATE265458T1 (el) |
AU (1) | AU3951899A (el) |
BG (1) | BG65119B1 (el) |
BR (1) | BR9911365A (el) |
CA (1) | CA2335492C (el) |
CZ (1) | CZ20004727A3 (el) |
DE (1) | DE69916833T2 (el) |
DK (1) | DK1087970T3 (el) |
EA (1) | EA005852B1 (el) |
ES (1) | ES2219018T3 (el) |
FR (1) | FR14C0019I2 (el) |
GE (1) | GEP20074227B (el) |
GT (1) | GT199900090A (el) |
HK (1) | HK1036801A1 (el) |
HR (1) | HRP20000885B1 (el) |
HU (1) | HUP0102574A3 (el) |
ID (1) | ID26698A (el) |
IL (1) | IL139586A0 (el) |
MA (1) | MA26654A1 (el) |
MY (1) | MY125916A (el) |
NO (1) | NO318784B1 (el) |
NZ (1) | NZ518444A (el) |
OA (1) | OA11572A (el) |
PA (1) | PA8476001A1 (el) |
PE (1) | PE20000698A1 (el) |
PL (1) | PL198640B1 (el) |
PT (1) | PT1087970E (el) |
RS (1) | RS50087B (el) |
SA (1) | SA99200283B1 (el) |
SK (1) | SK286640B6 (el) |
TN (1) | TNSN99126A1 (el) |
TR (1) | TR200003719T2 (el) |
TW (1) | TW505646B (el) |
WO (1) | WO1999065908A1 (el) |
Families Citing this family (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
TW505646B (en) * | 1998-06-19 | 2002-10-11 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds |
PL218519B1 (pl) | 1999-12-10 | 2014-12-31 | Pfizer Prod Inc | Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie |
SK17342002A3 (sk) * | 2000-06-26 | 2004-06-08 | Pfizer Products Inc. | Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu |
WO2002024667A1 (en) | 2000-09-20 | 2002-03-28 | Merck Patent Gmbh | 4-amino-quinazolines |
US7067550B2 (en) * | 2000-11-03 | 2006-06-27 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's Disease |
DE10063294A1 (de) * | 2000-12-19 | 2002-07-04 | Aventis Pharma Gmbh | Substituierte Heterocyclo-Norbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
JP2004528295A (ja) * | 2001-01-30 | 2004-09-16 | サイトピア ピーティワイ リミテッド | キナーゼ阻害方法 |
RU2269527C2 (ru) | 2001-02-12 | 2006-02-10 | Ф.Хоффманн-Ля Рош Аг | Производные пиридопиримидинов, способы их получения и фармацевтическая композиция на их основе |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0115393D0 (en) * | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
ATE401079T1 (de) * | 2001-06-29 | 2008-08-15 | Ab Science | Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen |
EP1401413B1 (en) | 2001-06-29 | 2006-11-22 | AB Science | Use of tyrosine kinase inhibitions for treating allergic diseases |
JP2005500041A (ja) | 2001-06-29 | 2005-01-06 | アブ サイエンス | 強力で選択的かつ非毒性のc−kit阻害剤 |
EP1401416B1 (en) * | 2001-06-29 | 2006-10-25 | AB Science | Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd) |
DK1401415T3 (da) | 2001-06-29 | 2006-10-16 | Ab Science | Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme |
US7323469B2 (en) | 2001-08-07 | 2008-01-29 | Novartis Ag | 7H-pyrrolo[2,3-d]pyrimidine derivatives |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
US7829566B2 (en) | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
CA2472619A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Corporation | Fused pyrimidine derivates as rho-kinase inhibitors |
CA2473910C (en) | 2002-01-23 | 2011-03-15 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
JP4469179B2 (ja) | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Rhoキナーゼ阻害剤としてのピリミジン誘導体 |
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
EP1388541A1 (en) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
EP1572213A1 (en) | 2002-11-26 | 2005-09-14 | Pfizer Products Inc. | Method of treatment of transplant rejection |
EP1682564A1 (en) * | 2003-10-27 | 2006-07-26 | Genelabs Technologies, Inc. | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES |
CA2545192A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
WO2005095357A2 (en) * | 2004-03-30 | 2005-10-13 | Taisho Pharmaceutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
US7358250B2 (en) | 2004-06-29 | 2008-04-15 | Amgen Inc. | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity |
EP1797054A2 (en) | 2004-08-02 | 2007-06-20 | OSI Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
AR054416A1 (es) * | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
PL1891066T3 (pl) | 2005-05-13 | 2011-05-31 | Irm Llc | Związki i kompozycje jako inhibitory kinazy białkowej |
KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
EP1926735A1 (en) | 2005-09-22 | 2008-06-04 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
SG151327A1 (en) * | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
CN103214483B (zh) | 2005-12-13 | 2014-12-17 | 因塞特公司 | 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶 |
WO2007126841A2 (en) * | 2006-03-29 | 2007-11-08 | Foldrx Pharmaceuticals, Inc. | Inhibition of alpha-synuclein toxicity |
EP3719018A1 (en) | 2006-04-25 | 2020-10-07 | Astex Therapeutics Ltd | Purine and deazapurine derivatives as pharmaceutical compounds |
EP2121692B1 (en) | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
KR20090106604A (ko) | 2007-01-12 | 2009-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 피리딘 화합물 |
JP2010523522A (ja) * | 2007-04-02 | 2010-07-15 | パラウ・フアルマ・ソシエダツド・アノニマ | Jak3阻害剤としてのピロロピリミジン誘導体 |
CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
KR101549876B1 (ko) | 2007-06-13 | 2015-09-03 | 인사이트 코포레이션 | 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염 |
DE102007027800A1 (de) | 2007-06-16 | 2008-12-18 | Bayer Healthcare Ag | Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung |
WO2009061903A2 (en) * | 2007-11-10 | 2009-05-14 | Landmark Graphics Corporation | Systems and methods for workflow automation, adaptation and integration |
ES2893580T3 (es) * | 2007-11-28 | 2022-02-09 | Dana Farber Cancer Inst Inc | Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso |
MX2010008719A (es) | 2008-02-06 | 2010-09-24 | Novartis Ag | Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina. |
PT2247592E (pt) * | 2008-02-25 | 2011-11-03 | Hoffmann La Roche | Inibidores de pirrolpirazina-cinase |
JP5275371B2 (ja) | 2008-03-11 | 2013-08-28 | インサイト・コーポレイション | Jak阻害剤としてのアゼチジン誘導体およびシクロブタン誘導体 |
WO2009115084A2 (de) * | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Neue pyrrolopyrimidin-derivate und deren verwendungen |
WO2010003133A2 (en) * | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
WO2010014930A2 (en) * | 2008-08-01 | 2010-02-04 | Biocryst Pharmaceuticals, Inc. | Therapeutic agents |
WO2010020905A1 (en) | 2008-08-20 | 2010-02-25 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
US8385364B2 (en) * | 2008-09-24 | 2013-02-26 | Nec Laboratories America, Inc. | Distributed message-passing based resource allocation in wireless systems |
AU2010239396B2 (en) | 2009-04-20 | 2016-06-23 | Auspex Pharmaceuticals, Llc | Piperidine inhibitors of Janus Kinase 3 |
RS59632B1 (sr) | 2009-05-22 | 2020-01-31 | Incyte Holdings Corp | 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori |
AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
EP2451813B1 (en) | 2009-07-08 | 2014-10-01 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
TW201111385A (en) * | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
US9249145B2 (en) | 2009-09-01 | 2016-02-02 | Incyte Holdings Corporation | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
BR112012008267B1 (pt) | 2009-10-09 | 2022-10-04 | Incyte Holdings Corporation | Derivados hidroxila, ceto e glucuronida de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1- il)-3-ciclopentilpropanonitrila |
EP2488524B1 (en) | 2009-10-15 | 2013-07-03 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
EP2513114B1 (en) * | 2009-12-18 | 2014-04-02 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
WO2011097087A1 (en) | 2010-02-05 | 2011-08-11 | Pfizer Inc. | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
EP2360158A1 (en) * | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
TWI766281B (zh) | 2010-03-10 | 2022-06-01 | 美商英塞特控股公司 | 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物 |
WO2012003829A1 (en) * | 2010-07-09 | 2012-01-12 | Leo Pharma A/S | Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
TW201249845A (en) | 2010-11-19 | 2012-12-16 | Incyte Corp | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
JP5917544B2 (ja) | 2010-11-19 | 2016-05-18 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Jak阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン |
EP2661436B1 (en) | 2011-01-07 | 2016-04-13 | Leo Pharma A/S | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof |
ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
MX2013013331A (es) * | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Derivados de azaindol como inhibidores de tirosina-cinasas. |
WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
JP2014521725A (ja) | 2011-08-10 | 2014-08-28 | ノバルティス・ファルマ・アクチェンゲゼルシャフト | JAKPI3K/mTOR併用療法 |
TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
WO2013082476A1 (en) * | 2011-11-30 | 2013-06-06 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
MX358679B (es) * | 2011-12-21 | 2018-08-31 | Jiangsu Hengrui Medicine Co | Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo. |
WO2013173720A1 (en) | 2012-05-18 | 2013-11-21 | Incyte Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
ES2592404T3 (es) | 2012-05-21 | 2016-11-30 | Bayer Pharma Aktiengesellschaft | Benzotienopirimidinas sustituidas |
PE20150153A1 (es) * | 2012-06-29 | 2015-02-05 | Pfizer | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 |
TWI574946B (zh) * | 2012-07-17 | 2017-03-21 | 葛蘭素史密斯克藍智慧財產權有限公司 | 化合物 |
ES2707627T3 (es) | 2012-07-20 | 2019-04-04 | Zoetis Services Llc | Régimen de dosificación para inhibidores de Janus Quinasa (JAK) |
TW201412740A (zh) | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
US9593115B2 (en) | 2012-09-21 | 2017-03-14 | Advinus Therapeutics Ltd. | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof |
CN102936251A (zh) * | 2012-11-05 | 2013-02-20 | 上海毕得医药科技有限公司 | 一种吡咯并[2,3-d]嘧啶衍生物的制备方法 |
SG10202111768XA (en) | 2012-11-15 | 2021-11-29 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
KR101683061B1 (ko) * | 2013-02-07 | 2016-12-07 | 한국과학기술연구원 | JAK-3 저해제로 유용한 7H-피롤로[2,3-d]피리미딘-4-싸이올 유도체 |
JP6145179B2 (ja) * | 2013-02-22 | 2017-06-07 | ファイザー・インク | ヤヌス関連キナーゼ(JAK)の阻害剤としてのピロロ[2,3−d]ピリミジン誘導体 |
LT2964650T (lt) | 2013-03-06 | 2019-04-25 | Incyte Holdings Corporation | Būdai ir tarpiniai junginiai, skirti jak inhibitoriaus gamybai |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
SI3030227T1 (sl) | 2013-08-07 | 2020-08-31 | Incyte Corporation | Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1 |
CN107417684A (zh) | 2013-12-05 | 2017-12-01 | 辉瑞公司 | 杂环丙烯酰胺 |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
JP6585158B2 (ja) | 2014-08-12 | 2019-10-02 | ファイザー・インク | ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体 |
ES2928757T3 (es) | 2015-05-01 | 2022-11-22 | Pfizer | Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa |
PT3305788T (pt) * | 2015-05-29 | 2020-09-25 | Wuxi Fortune Pharmaceutical Co Ltd | Inibidor da janus cinase |
KR101771219B1 (ko) | 2015-08-21 | 2017-09-05 | 양지화학 주식회사 | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 |
EP3350178B1 (en) | 2015-09-14 | 2021-10-20 | Pfizer Inc. | Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors |
CN106831779B (zh) * | 2015-11-28 | 2019-07-19 | 南昌弘益药业有限公司 | 一类jak激酶抑制剂的新化合物 |
JP6568324B2 (ja) | 2016-02-16 | 2019-08-28 | ゾエティス・サービシーズ・エルエルシー | 7H−ピロロ[2,3−d]ピリミジン化合物の調製方法 |
CN107098908B (zh) * | 2016-02-23 | 2021-01-08 | 欣凯医药科技(上海)有限公司 | 一种吡咯并嘧啶类化合物的制备方法和应用 |
EP3555074B1 (en) | 2016-12-14 | 2022-07-27 | Intervet International B.V. | Aminopyrazoles as selective janus kinase inhibitors |
MX2021005334A (es) * | 2018-11-05 | 2021-06-23 | Avista Pharma Solutions Inc | Compuestos quimicos. |
BR112021011578A2 (pt) | 2018-12-31 | 2021-08-31 | Biomea Fusion, Llc | Inibidores irreversíveis de interação menina-mll |
TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
EP3946606A1 (en) | 2019-03-27 | 2022-02-09 | Insilico Medicine IP Limited | Bicyclic jak inhibitors and uses thereof |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CA3201608A1 (en) | 2020-12-18 | 2022-06-23 | Boehringer Ingelheim Animal Health USA Inc. | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof |
CA3229150A1 (en) | 2021-08-20 | 2023-02-23 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cance |
WO2023029943A1 (zh) * | 2021-09-03 | 2023-03-09 | 星药科技(北京)有限公司 | 一种芳杂环化合物及其制备方法和用途 |
WO2023055731A1 (en) * | 2021-09-28 | 2023-04-06 | Sanford Burnham Prebys Medical Discovery Institute | Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof |
CA3242449A1 (en) | 2021-12-24 | 2023-06-29 | Intervet International B.V. | Use of aminopyrazole compounds |
GB202215132D0 (en) * | 2022-10-13 | 2022-11-30 | Norwegian Univ Sci & Tech Ntnu | Compound |
GB202215117D0 (en) * | 2022-10-13 | 2022-11-30 | Norwegian Univ Sci & Tech Ntnu | Compound |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
GB915303A (en) | 1958-03-13 | 1963-01-09 | Wellcome Found | Pyrrolo[2,3-d]pyrimidine derivatives and the manufacture thereof |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5389509A (en) | 1993-10-04 | 1995-02-14 | Eastman Kodak Company | Ultrathin high chloride tabular grain emulsions |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
EP0682027B1 (de) * | 1994-05-03 | 1997-10-15 | Novartis AG | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
ATE247469T1 (de) * | 1995-06-07 | 2003-09-15 | Pfizer | Heterocyclische kondensierte pyrimidin-derivate |
DE69618959T2 (de) | 1995-07-05 | 2002-08-29 | E.I. Du Pont De Nemours And Co., Wilmington | Pyrimidone und ihre verwendug als fungizide |
US6140332A (en) * | 1995-07-06 | 2000-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
ATE201873T1 (de) | 1995-11-14 | 2001-06-15 | Pharmacia & Upjohn Spa | Aryl- und heteroaryl- purin- und pyridopyrimidin- derivate |
EP0888349B1 (en) | 1996-01-23 | 2002-05-22 | Novartis AG | Pyrrolopyrimidines and processes for their preparation |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
GB9604361D0 (en) * | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
US6207669B1 (en) | 1996-07-13 | 2001-03-27 | Glaxo Wellcome Inc. | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DE69738468T2 (de) | 1996-08-23 | 2009-01-08 | Novartis Ag | Substituierte pyrrolopyrimidine und verfahren zu ihrer herstellung |
CA2272705C (en) * | 1996-11-27 | 2003-03-18 | Pfizer Inc. | Fused bicyclic pyrimidine derivatives |
JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔2,3−d〕ピリミジンおよび4−アミノピリミジン |
US6187552B1 (en) | 1997-03-24 | 2001-02-13 | Pharmacia & Upjohn Company | Method for identifying inhibitors of JAK2/cytokine receptor binding |
US6080847A (en) * | 1997-12-04 | 2000-06-27 | Incyte Pharmaceuticals, Inc. | Proteins associated with cell proliferation |
US6310063B1 (en) | 1998-04-02 | 2001-10-30 | Neurogen Corporation | Aminoalkyl substituted pyrrolo [3,2-E]pyridine and pyrollo [2,3-b]pyrimidine derivatives: modulators of CRF1 receptors |
WO1999061428A1 (en) | 1998-05-28 | 1999-12-02 | Parker Hughes Institute | Quinazolines for treating brain tumor |
TW505646B (en) * | 1998-06-19 | 2002-10-11 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds |
WO2000000202A1 (en) | 1998-06-30 | 2000-01-06 | Parker Hughes Institute | Method for inhibiting c-jun expression using jak-3 inhibitors |
HUP0103386A3 (en) | 1998-08-21 | 2002-07-29 | Parker Hughes Inst St Paul | Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
PL218519B1 (pl) * | 1999-12-10 | 2014-12-31 | Pfizer Prod Inc | Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie |
SK17342002A3 (sk) * | 2000-06-26 | 2004-06-08 | Pfizer Products Inc. | Derivát pyrolo[2,3-d]pyrimidínu ako činidlo potlačujúce imunitu |
AU2009100870A4 (en) | 2008-10-01 | 2009-10-22 | Rock Tone Enterprise Co., Ltd. | Drive mechanism for dehydrator |
TWM358618U (en) | 2008-12-26 | 2009-06-11 | Rock Tone Entpr Co Ltd | Combination structure of mop holder and cleaning body |
-
1999
- 1999-06-14 TW TW088109926A patent/TW505646B/zh active
- 1999-06-14 WO PCT/IB1999/001100 patent/WO1999065908A1/en active IP Right Grant
- 1999-06-14 CA CA002335492A patent/CA2335492C/en not_active Expired - Lifetime
- 1999-06-14 AT AT99922454T patent/ATE265458T1/de not_active IP Right Cessation
- 1999-06-14 BR BR9911365-1A patent/BR9911365A/pt not_active Application Discontinuation
- 1999-06-14 RS YUP-785/00A patent/RS50087B/sr unknown
- 1999-06-14 ES ES99922454T patent/ES2219018T3/es not_active Expired - Lifetime
- 1999-06-14 TR TR2000/03719T patent/TR200003719T2/xx unknown
- 1999-06-14 IL IL13958699A patent/IL139586A0/xx active Protection Beyond IP Right Term
- 1999-06-14 EP EP99922454A patent/EP1087970B1/en not_active Expired - Lifetime
- 1999-06-14 OA OA1200000349A patent/OA11572A/en unknown
- 1999-06-14 EA EA200001203A patent/EA005852B1/ru not_active IP Right Cessation
- 1999-06-14 PL PL345123A patent/PL198640B1/pl unknown
- 1999-06-14 PT PT99922454T patent/PT1087970E/pt unknown
- 1999-06-14 SK SK1898-2000A patent/SK286640B6/sk not_active IP Right Cessation
- 1999-06-14 DE DE69916833T patent/DE69916833T2/de not_active Expired - Lifetime
- 1999-06-14 ID IDW20002644A patent/ID26698A/id unknown
- 1999-06-14 CZ CZ20004727A patent/CZ20004727A3/cs unknown
- 1999-06-14 JP JP2000554733A patent/JP4666762B2/ja not_active Expired - Lifetime
- 1999-06-14 KR KR10-2000-7014402A patent/KR100415791B1/ko not_active IP Right Cessation
- 1999-06-14 AU AU39518/99A patent/AU3951899A/en not_active Abandoned
- 1999-06-14 CN CN99807521A patent/CN1128800C/zh not_active Ceased
- 1999-06-14 HU HU0102574A patent/HUP0102574A3/hu unknown
- 1999-06-14 DK DK99922454T patent/DK1087970T3/da active
- 1999-06-16 PE PE1999000531A patent/PE20000698A1/es not_active Application Discontinuation
- 1999-06-16 MA MA25630A patent/MA26654A1/fr unknown
- 1999-06-16 PA PA19998476001A patent/PA8476001A1/es unknown
- 1999-06-16 TN TNTNSN99126A patent/TNSN99126A1/fr unknown
- 1999-06-17 AP APAP/P/1999/001584A patent/AP1021A/en active
- 1999-06-17 MY MYPI99002502A patent/MY125916A/en unknown
- 1999-06-17 AR ARP990102916A patent/AR016499A1/es active IP Right Grant
- 1999-06-18 GT GT199900090A patent/GT199900090A/es unknown
- 1999-06-28 SA SA99200283A patent/SA99200283B1/ar unknown
-
2000
- 2000-11-08 NZ NZ518444A patent/NZ518444A/en not_active Application Discontinuation
- 2000-12-18 NO NO20006453A patent/NO318784B1/no not_active IP Right Cessation
- 2000-12-19 HR HR20000885A patent/HRP20000885B1/xx not_active IP Right Cessation
-
2001
- 2001-01-08 BG BG105129A patent/BG65119B1/bg unknown
- 2001-09-19 US US09/956,645 patent/US6610847B2/en not_active Expired - Lifetime
- 2001-11-06 HK HK01107744A patent/HK1036801A1/xx not_active IP Right Cessation
-
2003
- 2003-05-20 US US10/442,807 patent/US6890929B2/en not_active Expired - Lifetime
-
2005
- 2005-02-23 US US11/064,873 patent/US7687507B2/en not_active Expired - Fee Related
-
2007
- 2007-04-25 GE GEAP200710007A patent/GEP20074227B/en unknown
- 2007-08-06 JP JP2007204429A patent/JP4971068B2/ja not_active Expired - Lifetime
-
2011
- 2011-11-11 JP JP2011247593A patent/JP2012041365A/ja active Pending
-
2014
- 2014-03-07 FR FR14C0019C patent/FR14C0019I2/fr active Active